SCHEMBL5633913

SCHEMBL5633913

O=C(O)COc1ccc(OC/C=C\c2ccc(-c3ccc(/C=C/COc4ccc(CC(=O)O)cc4Cl)cc3)cc2)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 6/20 0.47
TDP1 Q9NUW8 2/20 0.41
MCL1 Q07820 1/20 0.40
PPARG P37231 4/20 0.40
PPARA Q07869 4/20 0.40
LTB4R Q15722 3/20 0.39
LTB4R2 Q9NPC1 3/20 0.39
FFAR1 O14842 1/20 0.39
PTPN1 P18031 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.38
THRA P10827 1/20 0.38
THRB P10828 1/20 0.38
MEN1 O00255 1/20 0.38
NR1I2 O75469 1/20 0.38
LMNA P02545 1/20 0.38
PGR P06401 1/20 0.38
ADRB2 P07550 1/20 0.38
ADRB1 P08588 1/20 0.38
ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5633915 1.00 PPARD (0.47) PPARDTDP1MCL1PPARGPPARA
SCHEMBL5656286 0.86 PPARD (0.43) PPARDTDP1MCL1PPARGLTB4R
SCHEMBL5656293 0.86 PPARD (0.43) PPARDTDP1MCL1PPARGLTB4R
SCHEMBL14539235 0.86 PPARD (0.48) PPARDPPARGPPARALTB4RLTB4R2
SCHEMBL5633152 0.81 PPARA (0.63) PPARDPPARGPPARA
SCHEMBL5633149 0.81 PPARA (0.63) PPARDPPARGPPARA
SCHEMBL14539031 0.80 PPARD (0.55) PPARDTDP1PPARGPPARALTB4R
SCHEMBL5633466 0.80 PPARD (0.55) PPARDPPARGPPARA
SCHEMBL5633464 0.80 PPARD (0.55) PPARDPPARGPPARA
SCHEMBL27603308 0.78 PPARD (0.59) PPARDLTB4RLTB4R2PTPN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1438283-A1 DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE NOVO NORDISK A/S (DK) 2004-07-21 EP claimed
US-20030109579-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2003-06-12 US claimed
WO-2003033453-A1 DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE NOVO NORDISK A/S (DK) 2003-04-24 WO claimed
US-7220877-B2 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2007-05-22 US disclosed
EP-1438283-A1 DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE NOVO NORDISK A/S (DK) 2004-07-21 EP disclosed
US-20030109579-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2003-06-12 US disclosed
WO-2003033453-A1 DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE NOVO NORDISK A/S (DK) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109579-A1 Novel compounds, their preparation and use PPARG, PPARA, PPARD PPARD 3/4885TDP1 4097/4885MCL1 4039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.